What it is
IGF-1 LR3 is a long-acting IGF-1 analog discussed in muscle and recovery research. Human protocol data are not established, and hypoglycemia is a real concern.
Evidence boundary
Investigational. Do not present a human dosing schedule as a validated standard.
Trial evidence
No verified human trial found.
Preparation and measurement
Reconstitution: 1 mg vial + 3 mL BAC = 0.33 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–2 (titration) | 20 mcg | 6 U (0.06 mL) | Once daily | 140 mcg/week |
| Weeks 3–4 | 40 mcg | 12 U (0.12 mL) | Once daily | 280 mcg/week |
| Weeks 5–8 (target) | 50 mcg | 15 U (0.15 mL) | Once daily | 350 mcg/week |
Weeks 1–2 (titration)
- Dose
- 20 mcg
- Draw / measure
- 6 U (0.06 mL)
- Frequency
- Once daily
- Weekly total
- 140 mcg/week
Weeks 3–4
- Dose
- 40 mcg
- Draw / measure
- 12 U (0.12 mL)
- Frequency
- Once daily
- Weekly total
- 280 mcg/week
Weeks 5–8 (target)
- Dose
- 50 mcg
- Draw / measure
- 15 U (0.15 mL)
- Frequency
- Once daily
- Weekly total
- 350 mcg/week
Weekly totals apply only during the active phase.
Titration rules
-
Light (20 mcg/day): Conservative starting dose.
-
Standard (40 mcg/day): Common research dose.
-
Higher (80 mcg/day): Advanced research; significantly increased hypoglycemia risk.
-
Cycle structure: 4–6 weeks active, then 4–6 week break. Long-term continuous use risks receptor downregulation.
-
Critical timing: Eat carbohydrates within 30 minutes of dosing to manage hypoglycemia risk. Post-workout timing leverages the anabolic window.
-
Hypoglycemia
-
Joint pain
-
Whether a source is actually human data
-
Tissue overgrowth concerns at very high exposure
Practical rules
- Do not use animal-model dosing as human guidance.
- Monitor glucose closely if a researcher is comparing notes.
- Keep the interpretation separate from HGH discussions.